Recent

% | $
Quotes you view appear here for quick access.

AcelRx Pharmaceuticals, Inc. (ACRX) Message Board

  • calif_grl99 calif_grl99 Jan 11, 2013 8:17 AM Flag

    Major squeeze coming

    Shorts have loaded the boat... If phase 3 goes well, will be ugly for them...
    Dec 31: Short interest : 1,639,042
    http://www.nasdaq.com/symbol/acrx/short-interest

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • when in the phase 3?

      • 1 Reply to aapl_1000
      • Company has said publicly numerous times that data from their two phase 3 studies will be published in Q1 2013 (with an ARX-04 right behind these two). Given that their drug trial (ARX 01) already had very favorable phase 3 data which was data on Sufentanil "head to head" study vs. morphine, it seems likely that their three additional product candidates in clinical development (which is measuring Sufentanil ONLY against a placebo!!!!) - it should look very good by comparison:

        All 3 phase 3 studies are based on sufentanil:
        ARX-02 for the treatment of cancer breakthrough pain;
        ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and
        ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.

        Plus the recent buyers of the capital raise are locked up for 90 days, and cant sell their shares on good news. The pre-cap raise shareholder base is made up of 70% insiders, who are not selling. So given big short interest, its likely we could see a very nice squeeze, if data is good...

        Sentiment: Strong Buy

 
ACRX
4.58-0.1600(-3.38%)Apr 24 4:00 PMEDT